HIV reservoirs: The new frontier

AIDS Reviews

Volumn 13, Issue 1, 2011, Pages 13-29

  Iglesias Ussel, Maria D ^a   Romerio, Fabio ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

HAART; HIV; Persistence; Reservoirs

Indexed keywords

ANTIRETROVIRUS AGENT; BRYOSTATIN; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; CYTOKINE; DIDANOSINE; EFAVIRENZ; HISTONE METHYLTRANSFERASE; IMMUNOTOXIN; INDINAVIR; INTERLEUKIN 7; IONOMYCIN; LAMIVUDINE; NEUROTOXIN; NEVIRAPINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TRICHOSTATIN A; VALPROIC ACID; VIRUS DNA; VIRUS RNA; VORINOSTAT; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; ASTROCYTE; B LYMPHOCYTE; BLOOD; BLOOD BRAIN BARRIER; BONE MARROW; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CPG ISLAND; CYTOKINE RELEASE; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DISEASE COURSE; DISEASE MODEL; DNA METHYLATION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; EPIGENETICS; EXPERIMENTAL MOUSE; FOLLICULAR DENDRITIC CELL; GENE EXPRESSION; GENE SILENCING; GENOTYPE; HEMATOPOIETIC STEM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTONE METHYLATION; HIV ASSOCIATED DEMENTIA; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IN VITRO STUDY; INTESTINE; KIDNEY; LATENT VIRUS INFECTION; LIVER; LUNG; LYMPHOID ORGAN; MACACA MULATTA; MACACA NEMESTRINA; MACROPHAGE; MACROPHAGE MIGRATION; MAST CELL; MEMORY T LYMPHOCYTE; MICROGLIA; NERVE CELL LESION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN PHOSPHORYLATION; PROVIRUS; RETROVIRUS INFECTION; SEMINAL PLASMA; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN; T LYMPHOCYTE ACTIVATION; TESTIS; THYMUS; TRANSGENIC MOUSE; TREATMENT DURATION; UPREGULATION; UROGENITAL SYSTEM; VERTICAL TRANSMISSION; VIRAL TROPISM; VIRUS CARRIER; VIRUS ENTRY; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; PHYSIOLOGY; REVIEW; VIROLOGY;

ANTI-HIV AGENTS; HIV; HIV INFECTIONS; HUMANS; PROVIRUSES; VIRUS LATENCY;

EID: 79960632129     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (249)

1. Piatak M., Saag M., Yang L., et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993; 259:1749-1754 (Pubitemid 23114661)
2. Perelson A., Neumann A., Markowitz M., Leonard J., Ho D. HIV-1 dynamics in vivo:Virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586 (Pubitemid 26097216)
3. Perelson A., Essunger P., Cao Y., et al. Decay characteristics of HIV-1- infected compartments during combination therapy. Nature. 1997;387: 188-191 (Pubitemid 27209434)
4. Murray J., Emery S., Kelleher A., et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007;21:2315-2321 (Pubitemid 350287458)
5. Palmer S., Wiegand A., Maldarelli F., et al. New real-time reverse transcriptase- initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41:4531-4536 (Pubitemid 37259753)
6. Kim H., Perelson A. Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol. 2006;2:1232-1247 (Pubitemid 44656517)
7. Palmer S., Maldarelli F., Wiegand A., et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA. 2008;105:3879-3884 (Pubitemid 351723493)
8. Cohen Stuart J., Wensing A., Kovacs C., et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28:105-113 (Pubitemid 32971057)
9. Havlir D., Bassett R., Levitan D., et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286: 171-179 (Pubitemid 32640848)
10. Phillips A., Ledergerber B., Horban A., et al. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS. 2004;18:1795-1804 (Pubitemid 39179631)
11. Ortiz G., Wellons M., Brancato J., et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA. 2001;98:13288-13293 (Pubitemid 33051355)
12. Dinoso J., Kim S., Wiegand A., et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2009;106:9403-9408
13. Ramratnam B., Ribeiro R., He T., et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr. 2004;35:33-37 (Pubitemid 38044779)
14. Kieffer T., Finucane M., Nettles R., et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection:Virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis. 2004;189: 1452-1465 (Pubitemid 38543595)
15. Alexaki A., Liu Y., Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res. 2008;6:388-400.
16. Malim M., Cullen B. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE:Implications for HIV-1 latency. Cell. 1991;65:241-248 (Pubitemid 121006055)
17. Lassen K., Ramyar K., Bailey J., Zhou Y., Siliciano R. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog. 2006;2:e68.
18. Harper M., Marselle L., Gallo R., Wong-Staal F. Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci USA. 1986;83:772-776 (Pubitemid 16035557)
19. Schnittman S., Psallidopoulos M., Lane H., et al. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science. 1989;245:305-308 (Pubitemid 19196650)
20. Psallidopoulos M., Schnittman S., Thompson L., et al. Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J Virol. 1989; 63:4626-4631 (Pubitemid 19257837)
21. Chun T., Finzi D., Margolick J., Chadwick K., Schwartz D., Siliciano R. In vivo fate of HIV-1-infected T cells:Quantitative analysis of the transition to stable latency. Nat Med. 1995;1:1284-1290
22. Blankson J., Persaud D., Siliciano R. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53:557-593 (Pubitemid 34177896)
23. Chomont N., El-Far M., Ancuta P., et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893-900.
24. Chun T., Carruth L., Finzi D., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387: 183-188 (Pubitemid 27209433)
25. Pierson T., McArthur J., Siliciano R. Reservoirs for HIV-1:Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000;18:665-708. (Pubitemid 30365394)
26. Wightman F., Solomon A., Khoury G., et al. Both CD31(+) and CD31 naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis. 2010;202: 1738-1748
27. Krishnan V., Zeichner S. Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency. J Virol. 2004;78:9458-9473 (Pubitemid 39096554)
28. Chugh P., Bradel-Tretheway B., Monteiro-Filho C., et al. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology. 2008;5:11.
29. Chugh P., Fan S., Planelles V., Maggirwar S., Dewhurst S., Kim B. Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line. J Mol Biol. 2007; 366:67-81. (Pubitemid 46137968)
30. Klase Z., Winograd R., Davis J., et al. HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology. 2009;6:18.
31. Finzi D., Blankson J., Siliciano J., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517 (Pubitemid 29220209)
32. Siliciano J., Siliciano R. Latency and viral persistence in HIV-1 infection. J Clin Invest. 2000;106:823-825
33. Strain M., Gunthard H., Havlir D., et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV:Intrinsic stability predicts life-long persistence. Proc Natl Acad Sci USA. 2003;100:4819-4824 (Pubitemid 36457812)
34. Strain M., Little S., Daar E., et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005;191:1410-1418 (Pubitemid 40563351)
35. Richman D., Margolis D., Delaney M., Greene W., Hazuda D., Pomerantz R. The challenge of finding a cure for HIV infection. Science. 2009;323: 1304-1307
36. Trono D., Van Lint C., Rouzioux C., et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010;329:174-180
37. Choudhary S., Margolis D. Curing HIV:Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol. 2011;51:397-418.
38. Marban C., Suzanne S., Dequiedt F., et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J. 2007;26:412-423 (Pubitemid 46160942)
39. Cosenza M., Zhao M., Si Q., Lee S. Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol. 2002;12:442-455 (Pubitemid 35154931)
40. Zink M., Clements J. A novel simian immunodeficiency virus model that provides insight into mechanisms of human immunodeficiency virus central nervous system disease. J Neurovirol. 2002;8(Suppl 2):42-48 (Pubitemid 36097775)
41. Liu Y., Liu H., Kim B., et al. CD4-independent infection of astrocytes by human immunodeficiency virus type 1:Requirement for the human mannose receptor. J Virol. 2004;78:4120-4133 (Pubitemid 38437218)
42. Trillo-Pazos G., Diamanturos A., Rislove L., et al. Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol. 2003;13:144-154 (Pubitemid 36460815)
43. Bagasra O., Lavi E., Bobroski L., et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals:Identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS. 1996;10:573-585 (Pubitemid 26162985)
44. Nuovo G., Gallery F., MacConnell P., Braun A. In situ detection of polymerase chain reaction-amplified HIV-1 nucleic acids and tumor necrosis factor-alpha RNA in the central nervous system. Am J Pathol. 1994;144:659-666 (Pubitemid 24172054)
45. Takahashi K., Wesselingh S., Griffin D., McArthur J., Johnson R., Glass J. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol. 1996; 39:705-711 (Pubitemid 26183806)
46. Churchill M., Wesselingh S., Cowley D., et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol. 2009;66:253-258
47. Chiodi F., Fuerstenberg S., Gidlund M., Asjo B., Fenyo E. Infection of brainderived cells with the human immunodeficiency virus. J Virol. 1987; 61:1244-1247 (Pubitemid 17044040)
48. Carroll-Anzinger D., Al-Harthi L. Gamma interferon primes productive human immunodeficiency virus infection in astrocytes. J Virol. 2006; 80:541-544
49. Folks T., Kessler S., Orenstein J., Justement J., Jaffe E., Fauci A. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science. 1988;242:919-922 (Pubitemid 19015253)
50. Stanley S., Kessler S., Justement J., et al. CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol. 1992;149:689-697
51. Carter C., Onafuwa-Nuga A., McNamara L., et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med. 2010;16:446-451
52. Zhang J., Crumpacker C. Hematopoietic stem and progenitor cells in HIV/AIDS and immune reconstitution. Cell Res. 2010;20:745-747
53. Re M., Zauli G., Gibellini D., et al. Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. AIDS. 1993;7:1049-1055 (Pubitemid 23246447)
54. Neal T., Holland H., Baum C., et al. CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood. 1995;86:1749-1756
55. Molina J., Scadden D., Sakaguchi M., Fuller B., Woon A., Groopman J. Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. Blood. 1990;76:2476-2482
56. Davis B., Schwartz D., Marx J., et al. Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. J Virol. 1991;65:1985-1990
57. De Luca A., Teofili L., Antinori A., et al. Haemopoietic CD34+ progenitor cells are not infected by HIV-1 in vivo but show impaired clonogenesis. Br J Haematol. 1993;85:20-24 (Pubitemid 23291468)
58. Stella C., Ganser A., Hoelzer D. Defective in vitro growth of the hemopoietic progenitor cells in the acquired immunodeficiency syndrome. J Clin Invest. 1987;80:286-293 (Pubitemid 17132931)
59. Steinberg H., Crumpacker C., Chatis P. In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus. J Virol. 1991;65:1765-1769
60. Chaudhary P., Mechetner E., Roninson I. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992;80:2735-2739
61. Drach D., Zhao S., Drach J., et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood. 1992;80:2729-2734
62. Legrand O., Perrot J., Tang R., et al. Expression of the multidrug resistance- associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Br J Haematol. 1996; 94:23-33. (Pubitemid 26232535)
63. Eilers M., Roy U., Mondal D. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp Biol Med (Maywood). 2008;233:1149-1160
64. Lucia M., Rutella S., Leone G., Vella S., Cauda R. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr. 2001;27:321-330 (Pubitemid 32729077)
65. Valentin A., Rosati M., Patenaude D., et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2002;99:7015-7020 (Pubitemid 34526249)
66. Sundstrom J., Little D., Villinger F., Ellis J., Ansari A. Signaling through Toll-like receptors triggers HIV-1 replication in latently infected mast cells. J Immunol. 2004;172:4391-4401 (Pubitemid 38375254)
67. Sundstrom J., Ellis J., Hair G., et al. Human tissue mast cells are an inducible reservoir of persistent HIV infection. Blood. 2007;109:5293-5300 (Pubitemid 46890550)
68. Nelson A., Auerbach A., Man Y. Failure to detect active virus replication in mast cells at various tissue sites of HIV patients by immunohistochemistry. Int J Biol Sci. 2009;5:603-610
69. Carter C., Ehrlich L. Cell biology of HIV-1 infection of macrophages. Annu Rev Microbiol. 2008;62:425-443
70. Sharova N., Swingler C., Sharkey M., Stevenson M. Macrophages archive HIV-1 virions for dissemination in trans. EMBO J. 2005;24:2481-2489 (Pubitemid 41032598)
71. Giri M., Nebozhyn M., Showe L., Montaner L. Microarray data on gene modulation by HIV-1 in immune cells:2000-2006. J Leukoc Biol. 2006;80:1031-1043 (Pubitemid 44646309)
72. Aquaro S., Calio R., Balzarini J., Bellocchi M., Garaci E., Perno C. Macrophages and HIV infection:Therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 2002;55:209-225 (Pubitemid 34718126)
73. Kim R., Fromm M., Wandel C., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-294 (Pubitemid 28067324)
74. Perno C., Aquaro S., Rosenwirth B., et al. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J Leukoc Biol. 1994;56:381-386 (Pubitemid 24295810)
75. Marsh M., Theusner K., Pelchen-Matthews A. HIV assembly and budding in macrophages. Biochem Soc Trans. 2009;37:185-189
76. Cavert W., Notermans D., Staskus K., et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997; 276:960-964 (Pubitemid 27209096)
77. Kesson A., Fear W., Williams L., Chang J., King N., Cunningham A. HIV infection of placental macrophages:Their potential role in vertical transmission. J Leukoc Biol. 1994;56:241-246 (Pubitemid 24295790)
78. Xu W., Santini P., Sullivan J., et al. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol. 2009;10:1008-1017
79. Qiao X., He B., Chiu A., Knowles D., Chadburn A., Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol. 2006;7:302-310
80. Sonza S., Mutimer H., Oelrichs R., et al. Monocytes harbour replicationcompetent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS. 2001;15:17-22. (Pubitemid 32055775)
81. Keele B., Tazi L., Gartner S., et al. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol. 2008;82:5548-5561 (Pubitemid 351705262)
82. Heath S., Tew J., Szakal A., Burton G. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature. 1995;377:740-744
83. Smith B., Gartner S., Liu Y., et al. Persistence of infectious HIV on follicular dendritic cells. J Immunol. 2001;166:690-696 (Pubitemid 32038494)
84. Hlavacek W., Wofsy C., Perelson A. Dissociation of HIV-1 from follicular dendritic cells during HAART:Mathematical analysis. Proc Natl Acad Sci USA. 1999;96:14681-14686 (Pubitemid 30019699)
85. Burton G., Keele B., Estes J., Thacker T., Gartner S. Follicular dendritic cell contributions to HIV pathogenesis. Semin Immunol. 2002;14:275-284 (Pubitemid 34969896)
86. Estes J., Keele B., Tenner-Racz K., et al. Follicular dendritic cell-mediated up-regulation of CXCR4 expression on CD4 T cells and HIV pathogenesis. J Immunol. 2002;169:2313-2322 (Pubitemid 34920971)
87. Thacker T., Zhou X., Estes J., et al. Follicular dendritic cells and human immunodeficiency virus type 1 transcription in CD4+ T cells. J Virol. 2009;83:150-158
88. Moir S., Malaspina A., Li Y., et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med. 2000;192:637-646
89. Davis L., Hjelle B., Miller V., et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology. 1992;42:1736-1739
90. Resnick L., Berger J., Shapshak P., Tourtellotte W. Early penetration of the blood-brain-barrier by HIV. Neurology. 1988;38:9-14. (Pubitemid 18028082)
91. Brack-Werner R. Astrocytes:HIV cellular reservoirs and important participants in neuropathogenesis. AIDS. 1999;13:1-22.
92. Torres-Munoz J., Stockton P., Tacoronte N., Roberts B., Maronpot R., Petito C. Detection of HIV-1 gene sequences in hippocampal neurons isolated from postmortem AIDS brains by laser capture microdissection. J Neuropathol Exp Neurol. 2001;60:885-892 (Pubitemid 32880596)
93. Lindl K., Marks D., Kolson D., Jordan-Sciutto K. HIV-associated neurocognitive disorder:Pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol. 2010;5:294-309.
94. Staprans S., Marlowe N., Glidden D., et al. Time course of cerebrospinal fluid responses to antiretroviral therapy:Evidence for variable compartmentalization of infection. AIDS. 1999;13:1051-1061 (Pubitemid 29361395)
95. Ellis R., Gamst A., Capparelli E., et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology. 2000; 54:927-936 (Pubitemid 30111354)
96. Cunningham P., Smith D., Satchell C., Cooper D., Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS. 2000;14:1949-1954
97. Stingele K., Haas J., Zimmermann T., et al. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology. 2001;56:355-361 (Pubitemid 32144147)
98. Haworth S., Christofalo B., Anderson R., Dunkle L. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 17:235-238
99. Lewis L., Venzon D., Church J., et al. Lamivudine in children with human immunodeficiency virus infection:A phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis. 1996;174:16-25.
100. Stahle L., Martin C., Svensson J., Sonnerborg A. Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet. 1997;350:1823. (Pubitemid 28036525)
101. Evers S., Rahmann A., Schwaag S., Frese A., Reichelt D., Husstedt I. Prevention of AIDS dementia by HAART does not depend on cerebrospinal fluid drug penetrance. AIDS Res Hum Retroviruses. 2004;20:483-491 (Pubitemid 38720961)
102. Rosok B., Brinchmann J., Voltersvik P., Olofsson J., Bostad L., Asjo B. Correlates of latent and productive HIV type-1 infection in tonsillar CD4(+) T cells. Proc Natl Acad Sci USA. 1997;94:9332-9336 (Pubitemid 27357829)
103. Yukl S., Gianella S., Sinclair E., et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010;202:1553-1561
104. Gunthard H., Havlir D., Fiscus S., et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis. 2001;183:1318-1327 (Pubitemid 32337113)
105. Brooks D., Kitchen S., Kitchen C., Scripture-Adams D.D., Zack J.A. Generation of HIV latency during thymopoiesis. Nat Med. 2001;7:459-464 (Pubitemid 32298549)
106. Chun T., Nickle D., Justement J., et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008;197:714-720 (Pubitemid 351364472)
107. Yukl S., Shergill A., McQuaid K., et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24:2451-2460
108. Zeitz M., Greene W., Peffer N., James S. Lymphocytes isolated from the intestinal lamina propria of normal nonhuman primates have increased expression of genes associated with T-cell activation. Gastroenterology. 1988;94:647-655 (Pubitemid 18073524)
109. Gulick R., Mellors J., Havlir D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739 (Pubitemid 27417972)
110. Taylor S., Van Heeswijk R., Hoetelmans R., et al. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS. 2000;14:1979-1984
111. Taylor S., Pereira A. Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect. 2001;77:4-11. (Pubitemid 32142781)
112. Taylor S., Back D., Drake S., et al. Antiretroviral drug concentrations in semen of HIV-infected men:Differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother. 2001;48:351-354 (Pubitemid 32898804)
113. Zhang H., Dornadula G., Beumont M., et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med. 1998;339:1803-1809 (Pubitemid 29005784)
114. Borzy M., Connell R., Kiessling A. Detection of human immunodeficiency virus in cell-free seminal fluid. J Acquir Immune Defic Syndr. 1988;1:419-424 (Pubitemid 19129847)
115. Muciaccia B., Filippini A., Ziparo E., Colelli F., Baroni C., Stefanini M. Testicular germ cells of HIV-seropositive asymptomatic men are infected by the virus. J Reprod Immunol. 1998;41:81-93. (Pubitemid 29017867)
116. Nuovo G., Becker J., Simsir A., Margiotta M., Khalife G., Shevchuk M. HIV-1 nucleic acids localize to the spermatogonia and their progeny. A study by polymerase chain reaction in situ hybridization. Am J Pathol. 1994; 144:1142-1148 (Pubitemid 24172075)
117. Muciaccia B., Corallini S., Vicini E., et al. HIV-1 viral DNA is present in ejaculated abnormal spermatozoa of seropositive subjects. Hum Reprod. 2007;22:2868-2878 (Pubitemid 351696819)
118. Sheth P., Kovacs C., Kemal K., et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS. 2009;23:2050-2054
119. Coombs R., Speck C., Hughes J., et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood:Evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis. 1998; 177:320-330 (Pubitemid 28063755)
120. Halfon P., Giorgetti C., Khiri H., et al. Semen may harbor HIV despite effective HAART: another piece in the puzzle. PLoS One. 2010;5: e10569.
121. Bull M., Learn G., McElhone S., et al. Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol. 2009;83:6020-6028
122. Fiore J., Suligoi B., Saracino A., et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS. 2003;17:2169-2176 (Pubitemid 37338890)
123. Nunnari G., Sullivan J., Xu Y., et al. HIV type 1 cervicovaginal reservoirs in the era of HAART. AIDS Res Hum Retroviruses. 2005;21:714-718 (Pubitemid 41254237)
124. Si-Mohamed A., Kazatchkine M., Heard I., et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis. 2000; 182:112-122 (Pubitemid 30497795)
125. Bruggeman L., Ross M., Tanji N., et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol. 2000;11:2079-2087
126. Tanji N., Ross M., Tanji K., et al. Detection and localization of HIV-1 DNA in renal tissues by in situ polymerase chain reaction. Histol Histopathol. 2006;21:393-401.
127. Marras D., Bruggeman L., Gao F., et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med. 2002;8:522-526 (Pubitemid 34546757)
128. Mikulak J., Teichberg S., Faust T., Schmidtmayerova H., Singhal P. HIV-1 harboring renal tubular epithelial cell interaction with T cells results in T cell trans-infection. Virology. 2009;385:105-114
129. Hatsukari I., Singh P., Hitosugi N., et al. DEC-205-mediated internalization of HIV-1 results in the establishment of silent infection in renal tubular cells. J Am Soc Nephrol. 2007;18:780-787 (Pubitemid 46434495)
130. Chun T., Engel D., Mizell S., Ehler L., Fauci A. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med. 1998;188:83-91. (Pubitemid 28328608)
131. Moriuchi H., Moriuchi M., Fauci A.S. Induction of HIV-1 replication by allogeneic stimulation. J Immunol. 1999;162:7543-7548 (Pubitemid 29277735)
132. Korin Y., Brooks D., Brown S., Korotzer A., Zack J. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol. 2002;76:8118-8123 (Pubitemid 34809066)
133. Scripture-Adams D., Brooks D., Korin Y., Zack J. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol. 2002;76:13077-13082 (Pubitemid 35386993)
134. Brooks D., Hamer D., Arlen P., et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity. 2003;19:413-423 (Pubitemid 37153417)
135. Shen A., Yang H., Zhou Y., et al. Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol. 2007;81:1660-1670 (Pubitemid 46214441)
136. Bosque A., Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood. 2009;113:58-65.
137. Burke B., Brown H., Marsden M., Bristol G., Vatakis D., Zack J. Primary cell model for activation-inducible human immunodeficiency virus. J Virol. 2007;81:7424-7434 (Pubitemid 47047831)
138. Burnett J., Lim K., Calafi A., Rossi J., Schaffer D., Arkin A. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol. 2010;84: 5958-5974
139. Gondois-Rey F., Biancotto A., Pion M., et al. Production of HIV-1 by resting memory T lymphocytes. AIDS. 2001;15:1931-1940 (Pubitemid 32980634)
140. Marini A., Harper J., Romerio F. An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol. 2008;181: 7713-7720
141. Sahu G., Lee K., Ji J., Braciale V., Baron S., Cloyd M. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology. 2006;355:127-137 (Pubitemid 44692775)
142. Saleh S., Solomon A., Wightman F., Xhilaga M., Cameron P., Lewin S. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection:A novel model of HIV-1 latency. Blood. 2007;110:4161-4164 (Pubitemid 351377777)
143. Swiggard W., Baytop C., Yu J., et al. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol. 2005;79:14179-14188 (Pubitemid 41552716)
144. Tyagi M., Pearson R., Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol. 2010;84:6425-6437
145. Yang H., Xing S., Shan L., et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest. 2009;119:3473-3486
146. Han Y., Wind-Rotolo M., Yang H., Siliciano J., Siliciano R. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol. 2007;5: 95-106. (Pubitemid 46151868)
147. Folks T., Justement J., Kinter A., Dinarello C., Fauci A. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science. 1987;238:800-802
148. Folks T., Clouse K., Justement J., et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA. 1989;86:2365-2368 (Pubitemid 19102509)
149. Antoni B., Rabson A., Kinter A., Bodkin M., Poli G. NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line. Virology. 1994;202:684-694
150. Jordan A., Bisgrove D., Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 2003;22:1868-1877 (Pubitemid 36460143)
151. Emiliani S., Fischle W., Ott M., Van Lint C., Amella C., Verdin E. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol. 1998;72:1666-1670 (Pubitemid 28116960)
152. Emiliani S., Van Lint C., Fischle W., et al. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci USA. 1996;93:6377-6381 (Pubitemid 26230313)
153. Pearson R., Kim Y., Hokello J., et al. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol. 2008;82:12291-12303
154. Tyagi M., Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 2007;26:4985-4995 (Pubitemid 350261291)
155. Yang H., Shen L., Siliciano R., Pomerantz J. Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proc Natl Acad Sci USA. 2009;106:6321-6326
156. Brown H., Zack J. Animal models of HIV-1 latency and persistence. Curr Opin HIV AIDS. 2006;1:103-107
157. Denton P., Garcia J. Novel humanized murine models for HIV research. Curr HIV/AIDS Rep. 2009;6:13-19
158. Choudhary S., Rezk N., Ince W., et al. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/- {gamma}c-/- mouse. J Virol. 2009;83:8254-8258
159. Van Rompay K. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res. 2010;85:159-175
160. Giuffre A., Higgins J., Buckheit R., North T. Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrob Agents Chemother. 2003;47:1756-1759 (Pubitemid 36548569)
161. Dinoso J., Rabi S., Blankson J., et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol. 2009;83:9247-9257
162. Lewis M., Norelli S., Collins M., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir:A basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology. 2010;7:21.
163. Clements J., Gama L., Graham D., Mankowski J., Zink M. A simian immunodeficiency virus macaque model of highly active antiretroviral treatment:Viral latency in the periphery and the central nervous system. Curr Opin HIV AIDS. 2011;6:37-42.
164. Deere J., Schinazi R., North T. Simian immunodeficiency virus macaque models of HIV latency. Curr Opin HIV AIDS. 2011;6:57-61.
165. Zink M., Brice A., Kelly K., et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis. 2010;202:161-170
166. Chun T., Engel D., Berrey M., Shea T., Corey L., Fauci A. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA. 1998;95:8869-8873 (Pubitemid 28350581)
167. Chun T., Davey R., Ostrowski M., et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med. 2000; 6:757-761 (Pubitemid 30469423)
168. Davey R., Bhat N., Yoder C., et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA. 1999; 96:15109-15114 (Pubitemid 30019773)
169. Imamichi H., Crandall K., Natarajan V., et al. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis. 2001;183:36-50. (Pubitemid 32043039)
170. Zhang L., Chung C., Hu B., et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest. 2000;106:839-845
171. Montaner J., Lima V., Barrios R., et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada:A population-based study. Lancet. 2010;376:532-539
172. Attia S., Egger M., Muller M., Zwahlen M., Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy:Systematic review and meta-analysis. AIDS. 2009;23:1397-1404
173. Donnell D., Baeten J., Kiarie J., et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy:A prospective cohort analysis. Lancet. 2010;375:2092-2098
174. UNAIDS, WHO. AIDS epidemic update. 2009.
175. Chun T., Justement J., Moir S., et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods:Implications for eradication of virus. J Infect Dis. 2007;195:1762-1764 (Pubitemid 46870248)
176. Chun T., Justement J., Murray D., et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir:Implications for eradication. AIDS. 2010;24: 2803-2808
177. Rosenberg E., Billingsley J., Caliendo A., et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447-1450 (Pubitemid 27509814)
178. Schmid A., Gianella S., Von Wyl V., et al. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS One. 2010;5:e13310.
179. Kaufmann D., Lichterfeld M., Altfeld M., et al. Limited durability of viral control following treated acute HIV infection. PLoS Med. 2004;1:e36.
180. Van Praag R., Prins J., Roos M., et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol. 2001;21:218-226 (Pubitemid 32434309)
181. Stellbrink H., Van Lunzen J., Westby M., et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS. 2002;16:1479-1487 (Pubitemid 34804212)
182. Wang F., Xu Y., Sullivan J., et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest. 2005;115:128-137 (Pubitemid 40385513)
183. Imamichi H., Degray G., Asmuth D., et al. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS. 2011; 25:159-164
184. Chan J., Greene W. NF-kappaB/Rel:Agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS. 2011;6:12-18
185. Marsden M., Xu J., Hamer D., Zack J. Short communication:Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages. AIDS Res Hum Retroviruses. 2008;24:1399-1404
186. Lueders K., De Rosa S., Valentin A., Pavlakis G., Roederer M., Hamer D. A potent anti-HIV immunotoxin blocks spreading infection by primary HIV type 1 isolates in multiple cell types. AIDS Res Hum Retroviruses. 2004;20:145-150 (Pubitemid 38280924)
187. Nath A., Clements J. Eradication of HIV from the brain: reasons for pause. AIDS. 2011 [Epub ahead of print].
188. Verdin E., Paras P., Van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J. 1993;12:3249-3259 (Pubitemid 23232756)
189. Naghavi M., Schwartz S., Sonnerborg A., Vahlne A. Long terminal repeat promoter/enhancer activity of different subtypes of HIV type 1. AIDS Res Hum Retroviruses. 1999;15:1293-1303 (Pubitemid 29449408)
190. Hiscott J., Kwon H., Genin P. Hostile takeovers:Viral appropriation of the NF-kappaB pathway. J Clin Invest. 2001;107:143-151 (Pubitemid 32096827)
191. Coiras M., Lopez-Huertas M., Rullas J., Mittelbrunn M., Alcami J. Basal shuttle of NF-kappaB/I kappaB alpha in resting T lymphocytes regulates HIV-1 LTR dependent expression. Retrovirology. 2007;4:56.
192. Williams S., Chen L., Kwon H., Ruiz-Jarabo C., Verdin E., Greene W.C. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 2006;25:139-149 (Pubitemid 43077303)
193. Jiang G., Espeseth A., Hazuda D., Margolis D. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol. 2007;81:10914-10923 (Pubitemid 47536066)
194. Imai K., Okamoto T. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem. 2006;281:12495-12505 (Pubitemid 43855336)
195. Du Chene I., Basyuk E., Lin Y., et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J. 2007;26:424-435 (Pubitemid 46160943)
196. Kauder S., Bosque A., Lindqvist A., Planelles V., Verdin E. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 2009;5:e1000495.
197. Kinoshita S., Chen B., Kaneshima H., Nolan G. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell. 1998;95:595-604. (Pubitemid 28544121)
198. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination:The control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-663 (Pubitemid 30365393)
199. Yik J., Chen R., Nishimura R., Jennings J., Link A., Zhou Q. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell. 2003;12:971-982 (Pubitemid 37352789)
200. Xue Y., Yang Z., Chen R., Zhou Q. A capping-independent function of MePCE in stabilizing 7SK snRNA and facilitating the assembly of 7SK snRNP. Nucleic Acids Res. 2010;38:360-369
201. He N., Jahchan N., Hong E., et al. A La-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. Mol Cell. 2008;29:588-599
202. Klase Z., Kale P., Winograd R., et al. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol. 2007;8:63.
203. Omoto S., Fujii Y. Regulation of human immunodeficiency virus 1 transcription by nef microRNA. J Gen Virol. 2005;86:751-755 (Pubitemid 40331255)
204. Huang J., Wang F., Argyris E., et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med. 2007;13:1241-1247 (Pubitemid 47530631)
205. Han Y., Siliciano R. Keeping quiet:MicroRNAs in HIV-1 latency. Nat Med. 2007;13:1138-1140
206. Chable-Bessia C., Meziane O., Latreille D., et al. Suppression of HIV-1 replication by microRNA effectors. Retrovirology. 2009;6:26.
207. Triboulet R., Mari B., Lin Y., et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science. 2007;315:1579-1582 (Pubitemid 46449475)
208. Powell D., Amaral M., Wu J., Maniatis T., Greene W.C. HIV Rev-dependent binding of SF2/ASF to the Rev response element:Possible role in Revmediated inhibition of HIV RNA splicing. Proc Natl Acad Sci USA. 1997;94:973-978 (Pubitemid 27074432)
209. Li Q., Verma I. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2:725-734
210. Huang B., Yang X., Zhou M., Ozato K., Chen L. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol. 2009;29:1375-1387
211. West M., Lowe A., Karn J. Activation of human immunodeficiency virus transcription in T cells revisited:NF-kappaB p65 stimulates transcriptional elongation. J Virol. 2001;75:8524-8537 (Pubitemid 32768957)
212. Barboric M., Nissen R., Kanazawa S., Jabrane-Ferrat N., Peterlin B. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell. 2001;8:327-337 (Pubitemid 32831550)
213. Williams S., Kwon H., Chen L., Greene W. Sustained induction of NFkappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol. 2007;81:6043-6056 (Pubitemid 46847040)
214. Manicassamy S., Gupta S., Sun Z. Selective function of PKC-theta in T cells. Cell Mol Immunol. 2006;3:263-270
215. Contreras X., Barboric M., Lenasi T., Peterlin B. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog. 2007;3:1459-1469 (Pubitemid 350085610)
216. Chen R., Liu M., Li H., et al. PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. Genes Dev. 2008;22:1356-1368 (Pubitemid 351717526)
217. Kohoutek J. P-TEFb- the final frontier. Cell Div. 2009;4:19.
218. He N., Pezda A., Zhou Q. Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Mol Cell Biol. 2006;26:7068-7076 (Pubitemid 44477686)
219. Zhang H. Reversal of HIV-1 latency with anti-microRNA inhibitors. Int J Biochem Cell Biol. 2009;41:451-454
220. McIlroy D., Autran B., Cheynier R., et al. Low infection frequency of macrophages in the spleens of HIV+ patients. Res Virol. 1996; 147:115-121 (Pubitemid 26108128)
221. Raport C., Gosling J., Schweickart V., Gray P., Charo I. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem. 1996;271:17161-17166 (Pubitemid 26244268)
222. Valentin A., Trivedi H., Lu W., Kostrikis L., Pavlakis G. CXCR4 mediates entry and productive infection of syncytia-inducing (X4) HIV-1 strains in primary macrophages. Virology. 2000;269:294-304. (Pubitemid 30210902)
223. Groot F., Van Capel T., Schuitemaker J., Berkhout B., De Jong E. Differential susceptibility of naive, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology. 2006;3:52.
224. Lee B., Sharron M., Montaner L., Weissman D., Doms R. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA. 1999;96:5215-5220 (Pubitemid 29214563)
225. Blaak H., Van't Wout A., Brouwer M., Hooibrink B., Hovenkamp E., Schuitemaker H. In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci USA. 2000; 97:1269-1274 (Pubitemid 30080848)
226. Albright A., Shieh J., Itoh T., et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol. 1999; 73:205-213 (Pubitemid 28565362)
227. Deichmann M., Kronenwett R., Haas R. Expression of the human immunodeficiency virus type-1 coreceptors CXCR-4 (fusin, LESTR) and CKR- 5 in CD34+ hematopoietic progenitor cells. Blood. 1997;89:3522-3528 (Pubitemid 27227074)
228. Fulcher D., Basten A. B cell life span:A review. Immunol Cell Biol. 1997;75:446-455
229. Margolis D. Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS. 2011;6:25-29
230. Lehrman G., Hogue I., Palmer S., et al. Depletion of latent HIV-1 infection in vivo:A proof-of-concept study. Lancet. 2005;366:549-555 (Pubitemid 41140329)
231. Edelstein L.C., Micheva-Viteva S., Phelan B., Dougherty J. Short communication:Activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses. 2009;25:883-887
232. Kiefer H., Hanley T., Marcello J., Karthik A., Viglianti G. Retinoic acid inhibition of chromatin remodeling at the human immunodeficiency virus type 1 promoter. Uncoupling of histone acetylation and chromatin remodeling. J Biol Chem. 2004;279:43604-43613 (Pubitemid 39390663)
233. Imai K., Togami H., Okamoto T. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem. 2010;285:16538-16545
234. Greiner D., Bonaldi T., Eskeland R., Roemer E., Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol. 2005;1:143-145
235. Marquez N., Calzado M., Sanchez-Duffhues G., et al. Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation. Biochem Pharmacol. 2008;75:1370-1380
236. Hezareh M., Moukil M., Szanto I., et al. Mechanisms of HIV receptor and co-receptor down-regulation by prostratin:Role of conventional and novel PKC isoforms. Antivir Chem Chemother. 2004;15:207-222 (Pubitemid 39145468)
237. Biancotto A., Grivel J., Gondois-Rey F., et al. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol. 2004;78:10507-10515 (Pubitemid 39258376)
238. Rullas J., Bermejo M., Garcia-Perez J., et al. Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir Ther. 2004;9:545-554 (Pubitemid 39150212)
239. Williams S., Chen L., Kwon H., et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem. 2004;279:42008-42017 (Pubitemid 39313652)
240. Warrilow D., Gardner J., Darnell G., Suhrbier A., Harrich D. HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS Res Hum Retroviruses. 2006;22:854-864 (Pubitemid 44757161)
241. Bocklandt S., Blumberg P., Hamer D. Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res. 2003;59:89-98. (Pubitemid 36934497)
242. Perez M., De Vinuesa A., Sanchez-Duffhues G., et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res. 2010;8:418-429
243. Bedoya L., Marquez N., Martinez N., et al. SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro. Biochem Pharmacol. 2009;77:965-978
244. Hamer D., Bocklandt S., McHugh L., et al. Rational design of drugs that induce human immunodeficiency virus replication. J Virol. 2003;77:10227-10236 (Pubitemid 37129666)
245. Lyakh L., Ghosh P., Rice N. Expression of NFAT-family proteins in normal human T cells. Mol Cell Biol. 1997;17:2475-2484 (Pubitemid 27175128)
246. Omoto S., Ito M., Tsutsumi Y., et al. HIV-1 nef suppression by virally encoded microRNA. Retrovirology. 2004;1:44.
247. Ghose R., Liou L., Herrmann C., Rice A. Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines. J Virol. 2001;75:11336-11343 (Pubitemid 33063224)
248. Ping Y., Rana T. DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. J Biol Chem. 2001;276:12951-12958
249. Coull J., He G., Melander C., et al. Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. J Virol. 2002;76:12349-12354 (Pubitemid 35304334)